Engrail Therapeutics, a San Diego, CA-based neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies, raised a $32m extension of Series A financing, which brings the total round to $64m.
Nan Fung Life Sciences (NFLS), the global investment platform of the Nan Fung Group, led this round following their leadership of the original Series A raise.
The company will use the proceeds to finance the advancement of their diverse pipeline, including its lead assets, ENX-101, ENX-102 and internal preclinical programs.
Led by Vikram Sudarsan, Ph.D., CEO and president, Engrail Therapeutics has assembled a diverse portfolio of assets with validated mechanisms through its dynamic model for advancing drugs aimed at treating life-limiting diseases of the nervous system. By adopting a ‘science-first’ approach, combined with a comprehensive view of clinical development strategy, regulatory considerations and intellectual property, the company can find differentiated assets with validated mechanisms of action for diseases where significant patient need still exists.
FinSMEs
04/08/2021